Structural thresholds and nonlinear acceleration in clinical trial failure: a generalised additive model and change-point analysis of 134,724 registered trials (2016–2025)

Abstract Background Prior analyses of clinical trial termination have primarily modelled protocol complexity as a linear predictor of termination risk. However, linear models cannot detect structural inflection points, defined as values beyond which marginal increases in protocol complexity produce disproportionate acceleration in termination probability. Identifying these inflection points would transform protocol complexity from a continuous risk factor into a concrete planning threshold for protocol design. Methods Using a population-based cohort of 134,724 interventional trials from ClinicalTrials.gov (2016–2025), we modelled the relationship between protocol design features and trial termination using generalised additive models (GAMs) with penalised regression splines. Structural change-points were evaluated using the PELT algorithm with 1000 bootstrap resamples and temporal validation (training cohort: 2016–2021; validation cohort: 2022–2025). Reviewer-requested supplementary analyses included multivariable logistic regression adjusting for trial phase, sponsor class, intervention characteristics, geographical scope, allocation, masking, and outcome burden; formal interaction modelling; model diagnostic assessment; follow-up maturity sensitivity analyses; entropy robustness analyses; and counterfactual scenario modelling. Results GAM smoothing functions confirmed highly non-linear relationships for eligibility criteria (edf = 17.15, P < 0.001), total endpoints (edf = 16.96, P < 0.001), and the Protocol-Burden Index (edf = 17.14, P < 0.001). Bootstrap-supported change-point analysis identified an eligibility threshold at 16 criteria (95% CI 16–21), while temporal validation identified a corresponding threshold at 21 criteria. Multivariable logistic regression confirmed that protocol complexity remained independently associated with trial termination after adjustment for major trial characteristics. Formal interaction analyses demonstrated significant effect modification by both trial phase and sponsor class. Model diagnostics demonstrated acceptable discrimination (AUC = 0.716) and good numerical stability. Entropy sensitivity analyses consistently showed higher termination rates among protocols with increasingly concentrated structural burden. Under an equal-susceptibility counterfactual scenario, redesign of above-threshold protocols to below-threshold complexity corresponded to an estimated reduction of 5560 observed terminations (26.2% of terminated trials) under the specified counterfactual scenario. Conclusions Clinical trial termination risk exhibits robust nonlinear associations with protocol complexity across multiple complementary analytical approaches. The identified eligibility threshold should be interpreted as a population-level planning benchmark rather than a deterministic cutoff. These findings support prospective evaluation of complexity-aware trial design strategies and provide quantitative benchmarks for future protocol optimisation.

Authors

Publication Details

Journal
Trials
Published
2026-11-14
DOI
https://doi.org/10.1186/s13063-026-10044-7
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Structural thresholds and nonlinear acceleration in clinical trial failure: a generalised additive model and change-point analysis of 134,724 registered trials (2016–2025)

Sam Adeyemi
2 links
Trials
Statistical Methods in Clinical Trials
article

Structural thresholds and nonlinear acceleration in clinical trial failure: a generalised additive model and change-point analysis of 134,724 registered trials (2016–2025)

Sam Adeyemi
article en

Abstract

Abstract Background Prior analyses of clinical trial termination have primarily modelled protocol complexity as a linear predictor of termination risk. However, linear models cannot detect structural inflection points, defined as values beyond which marginal increases in protocol complexity produce disproportionate acceleration in termination probability. Identifying these inflection points would transform protocol complexity from a continuous risk factor into a concrete planning threshold for protocol design. Methods Using a population-based cohort of 134,724 interventional trials from ClinicalTrials.gov (2016–2025), we modelled the relationship between protocol design features and trial termination using generalised additive models (GAMs) with penalised regression splines. Structural change-points were evaluated using the PELT algorithm with 1000 bootstrap resamples and temporal validation (training cohort: 2016–2021; validation cohort: 2022–2025). Reviewer-requested supplementary analyses included multivariable logistic regression adjusting for trial phase, sponsor class, intervention characteristics, geographical scope, allocation, masking, and outcome burden; formal interaction modelling; model diagnostic assessment; follow-up maturity sensitivity analyses; entropy robustness analyses; and counterfactual scenario modelling. Results GAM smoothing functions confirmed highly non-linear relationships for eligibility criteria (edf = 17.15, P < 0.001), total endpoints (edf = 16.96, P < 0.001), and the Protocol-Burden Index (edf = 17.14, P < 0.001). Bootstrap-supported change-point analysis identified an eligibility threshold at 16 criteria (95% CI 16–21), while temporal validation identified a corresponding threshold at 21 criteria. Multivariable logistic regression confirmed that protocol complexity remained independently associated with trial termination after adjustment for major trial characteristics. Formal interaction analyses demonstrated significant effect modification by both trial phase and sponsor class. Model diagnostics demonstrated acceptable discrimination (AUC = 0.716) and good numerical stability. Entropy sensitivity analyses consistently showed higher termination rates among protocols with increasingly concentrated structural burden. Under an equal-susceptibility counterfactual scenario, redesign of above-threshold protocols to below-threshold complexity corresponded to an estimated reduction of 5560 observed terminations (26.2% of terminated trials) under the specified counterfactual scenario. Conclusions Clinical trial termination risk exhibits robust nonlinear associations with protocol complexity across multiple complementary analytical approaches. The identified eligibility threshold should be interpreted as a population-level planning benchmark rather than a deterministic cutoff. These findings support prospective evaluation of complexity-aware trial design strategies and provide quantitative benchmarks for future protocol optimisation.

Trials
Good health and well-being
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon